
Branden Wolner
Dr. Wolner is a Biotechnology/Biopharma research leader with over 10 years' experience in innovation and management. At SelectX Pharmaceuticals he led the development of novel recombination-based technologies for gene replacement leading to expression of new natural product derivatives. Combined with traditional medicinal chemistry this led to a novel aminoglycoside antibiotic for the treatment of nosocomial pulmonary infections. Following this, Dr. Wolner led the strain and process improvement efforts for advanced cellulosic biofuels production at Qteros leading to two patent filings. At Dow AgroSciences, Dr. Wolner led the overhaul of the high throughput screening and metabolic engineering groups leading to new, improved strains for DAS' crown jewel products Spinosad and Spinetoram. More recently, Dr. Wolner led the development of novel biocatalysts for the conversion of low-rank coal to high value chemicals. He is now an independent consultant based in San Diego.
Address: United States
Address: United States
less
Related Authors
X. You
New York University
B. Fisslthaler
Goethe-Universität Frankfurt am Main
Uploads
Papers by Branden Wolner